Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer
In EGFR -mutated lung cancer, the duration of response to tyrosine kinase inhibitors (TKIs) is limited by the development of acquired drug resistance. Despite the crucial role played by apoptosis-related genes in tumor cell survival, how their expression changes as resistance to EGFR-TKIs emerges re...
Uloženo v:
| Vydáno v: | Cell death & disease Ročník 15; číslo 8; s. 580 - 11 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
09.08.2024
Springer Nature B.V Nature Publishing Group |
| Témata: | |
| ISSN: | 2041-4889, 2041-4889 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | In
EGFR
-mutated lung cancer, the duration of response to tyrosine kinase inhibitors (TKIs) is limited by the development of acquired drug resistance. Despite the crucial role played by apoptosis-related genes in tumor cell survival, how their expression changes as resistance to EGFR-TKIs emerges remains unclear. Here, we conduct a comprehensive analysis of apoptosis-related genes, including BCL-2 and IAP family members, using single-cell RNA sequence
(
scRNA-seq) and spatial transcriptomics (ST). scRNA-seq of
EGFR
-mutated lung cancer cell lines captures changes in apoptosis-related gene expression following EGFR-TKI treatment, most notably
BCL2L1
upregulation. scRNA-seq of
EGFR
-mutated lung cancer patient samples also reveals high
BCL2L1
expression, specifically in tumor cells, while
MCL1
expression is lower in tumors compared to non-tumor cells. ST analysis of specimens from transgenic mice with EGFR-driven lung cancer indicates spatial heterogeneity of tumors and corroborates scRNA-seq findings. Genetic ablation and pharmacological inhibition of
BCL2L1
/BCL-XL overcome or delay EGFR-TKI resistance. Overall, our findings indicate that
BCL2L1
/BCL-XL expression is important for tumor cell survival as EGFR-TKI resistance emerges. |
|---|---|
| Bibliografie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 2041-4889 2041-4889 |
| DOI: | 10.1038/s41419-024-06940-y |